Kantarjian et al53 assessed the efficacy and security of dasatinib, as in contrast with imatinib, for the very first-line therapy of CML-CP. Five hundred and nineteen patients with recently diagnosed CML-CP had been randomly assigned to obtain dasatinib at a dose of 100 mg after daily (259 patients) or imatinib https://ericj420hns5.blogdiloz.com/profile